LuYNiWQuX, et al. Spironolactone for preventing contrast-induced nephropathy after percutaneous coronary intervention in patients with acute myocardial infarction and chronic kidney disease. Angiology. 2025;76(10):969-80.
2.
ZhouQLiuKWuH, et al. Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats. PLoS One. 2012;7:e47360.
3.
ShangDGuanYLiuS, et al. Effectiveness and safety of spironolactone in the treatment of IgA nephropathy: a retrospective self-controlled study. Kidney Blood Press Res. 2024;49:687-98.
4.
EbadiZMoradiNFardT, et al. Captopril and spironolactone can attenuate diabetic nephropathy in Wistar rats by Targeting microRNA-192 and microRNA-29a/b/c. DNA Cell Biol. 2019;38(10):1134-42.
5.
PanagiotouATrendelenburgMHeijnenIAFM, et al. A randomized trial of recombinant human C1-esterase-inhibitor in the prevention of contrast-induced kidney injury. JACC Cardiovasc Interv. 2020;13:833-42.
6.
KusirisinPChattipakornSCChattipakornN.Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med. 2020;18:400.
7.
ZhangFLuZWangF.Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci. 2020;259:118379.
8.
Mejia-ViletJMRamirezVCruzCUribeNGambaGBobadillaNA.Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Ren Physiol. 2007;293:F78-F86.
9.
Sanchez-PozosKBarrera-ChimalJGarzon-MuvdiJ, et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant. 2012;27:3160-9.
10.
Barrera-ChimalJRochaLAmador-MartinezI, et al. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. Nephrol Dial Transplant. 2019;34:794-801.
